首页> 外文OA文献 >Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades
【2h】

Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades

机译:1979年至2010年收集的人类血清具有阻断抗体滴度至大流行GII.4的病毒超过三十年的孤立病毒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The emergence of pandemic GII.4 norovirus (NoV) strains has been proposed to occur due to changes in receptor usage and thereby to lead to immune evasion. To address this hypothesis, we measured the ability of human sera collected between 1979 and 2010 to block glycan binding of four pandemic GII. 4 noroviruses isolated in the last 4 decades. In total, 268 sera were investigated for 50% blocking titer (BT50) values of virus-like particles (VLPs) against pig gastric mucin (PGM) using 4 VLPs that represent different GII. 4 norovirus variants identified between 1987 and 2012. Pre- and postpandemic sera (sera collected before and after isolation of the reference NoV strain) efficiently prevented binding of VLP strains MD145 (1987), Grimsby (1995), and Houston (2002), but not the Sydney (2012) strain, to PGM. No statistically significant difference in virus-blocking titers was observed between pre- and postpandemic sera. Moreover, paired sera showed that blocking titers of amp;gt;= 160 were maintained over a 6-year period against MD145, Grimsby, and Houston VLPs. Significantly higher serum blocking titers (geometric mean titer [GMT], 1,704) were found among IgA-deficient individuals than among healthy blood donors (GMT, 90.9) (P amp;lt; 0.0001). The observation that prepandemic sera possess robust blocking capacity for viruses identified decades later suggests a common attachment factor, at least until 2002. Our results indicate that serum IgG possesses antibody-blocking capacity and that blocking titers can be maintained for at least 6 years against 3 decades of pandemic GII. 4 NoV. IMPORTANCE Human noroviruses (NoVs) are the major cause of acute gastroenteritis worldwide. Histo-blood group antigens (HBGAs) in saliva and gut recognize NoV and are the proposed ligands that facilitate infection. Polymorphisms in HBGA genes, and in particular a nonsense mutation in FUT2 (G428A), result in resistance to global dominating GII. 4 NoV. The emergence of new pandemic GII. 4 strains occurs at intervals of several years and is proposed to be attributable to epochal evolution, including amino acid changes and immune evasion. However, it remains unclear whether exposure to a previous pandemic strain stimulates immunity to a pandemic strain identified decades later. We found that prepandemic sera possess robust virus-blocking capacity against viruses identified several decades later. We also show that serum lacking IgA antibodies is sufficient to block NoV VLP binding to HBGAs. This is essential, considering that 1 in every 600 Caucasian children is IgA deficient.
机译:大流行的GII.4诺如病毒(NoV)菌株的出现是由于受体使用方法的改变而引起的,从而导致免疫逃逸。为了解决这个假设,我们测量了1979年至2010年收集的人类血清阻断四种大流行GII的聚糖结合的能力。在最近的40年中分离出了4种诺如病毒。总共,使用代表不同GII的4个VLP,对268个血清的病毒样颗粒(VLP)对猪胃粘蛋白(PGM)的50%阻断效价(BT50)值进行了研究。在1987年至2012年之间鉴定出4种诺如病毒变种。大流行前后,血清(分离参考NoV株之前和之后收集的血清)有效地阻止了VLP株MD145(1987),Grimsby(1995)和Houston(2002)的结合,但是而不是悉尼(2012)对PGM的压力。大流行前和大流行后血清之间的病毒阻断效价没有统计学上的显着差异。此外,成对的血清表明,在6年的时间里,针对MD145,Grimsby和休斯顿VLP的滴度保持在160以上。在IgA缺陷型个体中发现的血清阻断效价(几何平均效价[GMT],1,704)明显高于健康献血者(GMT,90.9)(P≤0.0001)。大流行前血清对病毒具有强大的阻断能力的观察表明,几十年后才发现,这是一个常见的附着因子,至少直到2002年为止。我们的结果表明,血清IgG具有抗体阻断能力,针对3的阻断效价可以维持至少6年。几十年的GII大流行。 11月4日重要事项人类诺如病毒(NoVs)是全球急性胃肠炎的主要原因。唾液和肠道中的组织血型抗原(HBGA)识别NoV,并且是促进感染的提议配体。 HBGA基因的多态性,特别是FUT2(G428A)的无意义突变,导致对总体优势GII的抵抗。 11月4日新的大流行GII的出现。 4株以每隔几年的间隔出现,并被认为是由于时代的演变,包括氨基酸变化和免疫逃逸。然而,尚不清楚暴露于先前的大流行毒株是否会刺激对几十年后确定的大流行毒株的免疫力。我们发现大流行前血清对几十年后发现的病毒具有强大的病毒阻断能力。我们还显示缺乏IgA抗体的血清足以阻断NoV VLP与HBGA的结合。考虑到每600名白人儿童中有1名IgA缺乏,这一点至关重要。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号